Evidence map›Paper›PMID 32296921›Full record

ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2020

[Treatment of ocular tuberculosis-an update].

Larissa Christina Brönnimann, Stefan Zimmerli, Justus Gerhard Garweg

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Larissa Christina BrönnimannAbteilung Infektiologie, Klinik für Innere Medizin, Kantonsspital Olten, Olten, Schweiz.
Stefan ZimmerliUniversitätsklinik für Infektiologie, Inselspital, Universitätsspital Bern, Bern, Schweiz.
Justus Gerhard GarwegBerner Augenklinik am Lindenhofspital, Swiss Eye Institute, Bremgartenstr. 119, 3012, Bern, Schweiz. justus.garweg@augenklinik-bern.ch.ORCID http://orcid.org/0000-0003-3973-5082
Berner Augenklinik am Lindenhofspital · CHKantonsschule Olten · CHUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberculous uveitis (TU) is initially usually not acute, accompanied by only slight visual disorders and affects otherwise healthy individuals so that the diagnosis is frequently primarily overlooked.

objectiveThis study was carried out to provide an update of the treatment options in suspected TU. MATERIAL AND

methodsA PubMed search was undertaken using the key terms uveitis AND tuberculosis AND treatment for manuscripts published within the last decade. Cross-identified articles relevant to the topic were also evaluated regarding their evidence based on the authors' expertise.

resultsWhen the suspicion of a TU is not supported by further investigations, the decision has to weigh up the risks and benefits of treatment. A response of the uveitis to antituberculous treatment (ATT) in 82% represents an important diagnostic indication. Based on this remarkably good response rate and an acceptable side effect profile of ATT, a generous indication seems reasonable. A lack of response or a paradox worsening of uveitis under treatment for manifestations of extrapulmonary tuberculosis, probably represent a hypersensitivity reaction to mycobacterial antigens and require additional corticosteroid treatment. Eales' disease, an isolated retinal vasculitis, is associated with TU but does not respond to ATT and requires laser ablation of the ischemic area.

conclusionTU typically affects otherwise healthy individuals without extraocular manifestations. Early consideration of TU and initiation of ATT ideally before the start of systemic corticosteroids is decisive for long-term functional recovery. Treatment success, defined as absence of new uveitic flares within 6 months of treatment cessation, is to be expected in at least 82%. In cases of paradox worsening or lack of response, additional anti-inflammatory treatment is required.

Indexed as

Retinal VasculitisTuberculosis, OcularUveitisAntitubercular AgentsHumansRetrospective StudiesAntitubercular AgentsAntituberculous therapyMycobacterium tuberculosisParadox worseningSerpiginous-like choroiditisToxicity

Identifiers

PMID32296921
OpenAlexW3017100459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.